Changes to the website
Sponsored By
Medicenna Trial
Please Click On The Above Banner For More Details
Braintumor Website

This is a list of chages to the website.

You can Subscribe to our RSS FEED: Subscribe to our RSS feed, which delivers brain tumor news and additions to the website via RSS.
(Click HERE for details on RSS.)

Displaying items 1 to 25 of about 4484

Next 25
Website Changes
09/24/2017 Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients
09/24/2017 How the poliovirus can be used to battle lethal cancers
09/19/2017 New math developments lead to more improved brain cancer treatment
09/14/2017 Treatment nonexistent for some glioblastoma patients
09/11/2017 DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme
09/11/2017 "Treatment Options for Glioblastoma and other Gliomas" Ben Williams` Aug 2017 Update
09/10/2017 How a Dallas reporter pushed the FDA for a new approach to treating brain cancer
09/09/2017 NCCN Announces First Patient Dosed in NCCN-Peregrine Pharmaceuticals Collaborative Study of Bavituximab
09/07/2017 Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas
09/06/2017 Zika Virus Kills Brain Tumor Cells, Researchers Find
09/06/2017
09/01/2017 Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields
09/01/2017 Lymphoma Patient’s Brain Tumor Disappeared After She Received JCAR017, Study Reports
08/27/2017 STELLAR trial for Recurrent Anaplastic Astrocytoma
08/27/2017 OPTUNE OPEN HOUSE - NY Sept 9
08/18/2017 Reengineering Immune System Cells to Fight Glioblastoma
08/16/2017 VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
08/16/2017 CHOP to lead new pediatric data resource center for research in childhood cancer, birth defects
08/15/2017 Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas
08/15/2017 Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas
08/15/2017 Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas
08/14/2017 Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
08/14/2017 Options to Treat a Glioblastoma
07/29/2017 Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.
07/24/2017 Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites